advertisement
Abstract #27802 Published in IGR 13-1
Control of intraocular pressure and fluctuation with fixed-combination brimonidinetimolol versus brimonidine or timolol monotherapy
Spaeth GL; Bernstein P; Caprioli J; Schiffman RMAmerican Journal of Ophthalmology 2011; 151: 93-99
Purpose To evaluate control of intraocular pressure (IOP) and IOP fluctuation in patients with ocular hypertension or glaucoma treated with fixed-combination brimonidinetimolol compared with brimonidine or timolol monotherapy. Design Post hoc analysis of data from 2 identical, 12-month, randomized, double-masked, multicenter trials. Methods Patients were treated bilaterally with fixed brimonidinetimolol twice a day (n = 385), brimonidine tartrate 0.2% 3 times a day (n = 382), or timolol 0.5% twice a day (n = 392). Diurnal IOP was measured at follow-up visits at weeks 2 and 6 and months 3, 6, 9, and 12. IOP fluctuation was defined as the standard deviation of IOP measurements. Results The percentage of patients with mean diurnal IOP <18 mm Hg and short-term (daily) IOP fluctuation (less-than or equal to)2 mm Hg was statistically significantly higher in the brimonidinetimolol group than in the brimonidine or timolol group at each follow-up visit (at month 12, brimonidinetimolol 43.0%; brimonidine 18.9%, timolol 33.5%, P (less-than or equal to) .017). At each hour (8 AM, 10 AM, 3 PM, and 5 PM), the percentage of patients with mean IOP <18 mm Hg and long-term (intervisit) IOP fluctuation (less-than or equal to)2 mm Hg was statistically significantly higher with brimonidinetimolol than with brimonidine or timolol alone (at 8 AM, brimonidinetimolol 41.0%, brimonidine 11.3%, timolol 23.7%, P < .001). Conclusions Patients treated with fixed-combination brimonidinetimolol were more likely than patients treated with either brimonidine or timolol alone to achieve a combination of low mean IOP and low short-term (daily) or long-term (intervisit) IOP fluctuation.
G. L. Spaeth. Wills Eye Institute, 840 Walnut Street, Philadelphia, PA 19107-5109, United States. gspaeth@willseye.org
Classification:
11.13.3 Betablocker and brimonidine (Part of: 11 Medical treatment > 11.13 Combination therapy)
6.1.2 Fluctuation, circadian rhythms (Part of: 6 Clinical examination methods > 6.1 Intraocular pressure measurement; factors affecting IOP)
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
